Action B1AX34 BAXTER INTERNATIONAL INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Communiqués Baxter International Inc. Sao Paulo

Actions

B1AX34

BRB1AXBDR004

Marché Fermé - Sao Paulo
Autres places de cotation
 20:48:42 05/07/2024 		Varia. 5j. Varia. 1 janv.
93,78 BRL +0,58 % Graphique intraday de Baxter International Inc. +0,58 % -1,12 %
08/07 Mise à jour sectorielle : Les valeurs financières progressent en préambule au marché MT
08/07 Mise à jour du secteur : Financier MT

Communiqués

Recherche
Voir les résultats
Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !
Inscription 100% Gratuite
Baxter International : Issues Urgent Medical Device Recall for Life2000 Ventilator Due to Potential Battery Charger Dongle Damage
PU
Baxter International : 2023 SASB Index
PU
Baxter publishes annual corporate responsibility report, highlighting continued focus on creating lasting impact
BU
Baxter International : 2023 Corporate Responsibility Report2022 Corporate Responsibility Report2022 Task Force for Climate-related Financial Disclosures (TCFD) Index2021 Corporate Responsibility Report
PU
Fitch Affirms and Withdraws Baxter's Ratings
AQ
Baxter to Present at Goldman Sachs 45th Annual Global Healthcare Conference
BU
New Cohort Study Data Shows Baxter's Expanded Hemodialysis, Known as HDx Therapy is associated with approximately 25% Lower Mortality Rate for up to Four Years
AQ
New Cohort Study Data Shows Baxter’s Expanded Hemodialysis – Known as HDx Therapy – Is Associated With Approximately 25% Lower Mortality Rate for up to Four Years
BU
Baxter to Present at Jefferies 2024 Global Healthcare Conference
BU
Baxter Announces Mission and Logo for Proposed Kidney Care Company Vantive
BU
Baxter Secures FDA Approval of Clinolipid (Lipid Injectable Emulsion) Neonatal and Pediatric Indication
BU
Baxter to Present at Bank of America 2024 Health Care Conference
BU
Baxter Declares Quarterly Dividend
BU
Baxter International : Q1 2024 Financial Schedules
PU
Baxter: Q1 Earnings Snapshot
AQ
Baxter Reports First-Quarter 2024 Results
BU
Tentarix Biotherapeutics Announces the Appointment of Andrew D. Kidd, MD, CFA, as CEO
AQ
Baxter Expands Pharmaceuticals Portfolio with New Injectable Products in the U.S.
BU
Baxter to Host First-Quarter 2024 Financial Results Conference Call for Investors
BU
Baxter Announces U.S. FDA Clearance of Novum IQ Large Volume Infusion Pump and Dose IQ Safety Software, Advancing Connected and Intelligent Infusion Therapy
BU
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action BAX
  4. Action B1AX34
  5. Actualités Baxter International Inc.
  6. Communiqués